Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Tally Hustace"'
Autor:
Nora St Victor Dely, Ulrick Liberus, Louis Herns Marcelin, Iszet Campo-Bustillo, Ronald Eveillard, Emmeline Lerebours, Michele Paul-Hanna, Emanise Muscadin, Tally Hustace, Paulonne Bien-Aime, Rony Saint Fleur, Eric R. Brown, Alejandro Mantero, Nelly Campo, Jose G. Romano, Ofelia A. Alvarez
Publikováno v:
Blood. 138:4054-4054
Background: There are significant limitations in Haiti for the diagnosis and management of sickle cell disease (SCD), including the non-availability of universal newborn screening (NBS) and transcranial Doppler (TCD) ultrasound screening, and the lac
Autor:
Tally Hustace, Alejandro Mantero, Ulrick Liberus, Mimose Voltaire, Ofelia A. Alvarez, Rony Saint Fleur
Publikováno v:
Pediatrics. 144(4)
BACKGROUND: Newborn screening provides early diagnosis for children with sickle cell disease (SCD), reducing disease-related mortality. We hypothesized that rapid point-of-care (POC) Sickle SCAN would be reliable in Haiti and would assist newborn scr
Autor:
Natasha M. Archer, Tally Hustace, Rita Bellevue, Mimose Voltaire, Ofelia A. Alvarez, Rony Saint Fleur, Romain Jean Louis, Jacqueline Gautier, Emmeline Lerebours
Publikováno v:
Blood advances. 2(Suppl 1)
Newborn screening (NBS) is one of the most important public health initiatives for decreasing mortality in children with sickle cell disease (SCD). This initiative requires a solid infrastructure and national support. In 2010, newborns were screened
Autor:
Tally Hustace, Rony Saint Fleur, Mimose Voltaire, Ofelia A. Alvarez, Rodrigueson Rizil, Ulrick Liberus
Publikováno v:
Blood. 132:3670-3670
Introduction: Until 2017, hemoglobinopathy newborn screening (NBS) was not offered in Haiti, a country with about 243,000 births per year. Sickle SCAN is a rapid point-of-care (POC) with lateral flow immunoassay technology, but its role in NBS is unk
Autor:
Ana Milena Sanchez Varela, Antonello Podda, Jay M. Fleisher, Ofelia A. Alvarez, Tally Hustace
Publikováno v:
Pediatric Blood & Cancer. 57:1039-1043
Background The objective was to investigate the specificity of the hemoglobinopathy newborn screening in premature neonates as compared to term neonates. Procedure The screening results from infants suspected to have hemoglobinopathy disease identifi
Autor:
Tally Hustace, MaryLou MacDermott, Brenda Martin, Scott T. Miller, Zhaoyu Luo, Betsy Rackoff, Lea Adix, Billie Fish, Lynn W. Wynn, Phillip Seaman, Lane G. Faughnan, Tracy Kelly, Glenda Thomas, Caroline Reed, Jennifer McDuffie, Ellen Debenham, Joan Marasciulo, Mary A. Murphy, Winfred C. Wang
Publikováno v:
Contemporary Clinical Trials. 31:558-563
Background Protocol-eligible subjects may not be candidates for research participation or may decline. To determine factors that affected accrual, we evaluated enrollment in BABY HUG, a multi-center, randomized, placebo-controlled Phase III trial of
Autor:
Tally, Hustace, Jay M, Fleisher, Ana Milena, Sanchez Varela, Antonello, Podda, Ofelia, Alvarez
Publikováno v:
Pediatric bloodcancer. 57(6)
The objective was to investigate the specificity of the hemoglobinopathy newborn screening in premature neonates as compared to term neonates.The screening results from infants suspected to have hemoglobinopathy disease identified by the Florida Newb
Autor:
Tracy Kelly, Joan Marasciulo, Renee C. Rees, Glenda Thomas, Scott T. Miller, Lane G. Faughnan, Elizabeth Rackoff, Jennifer Marshall, Mary Murphy, Caroline Reed, Daner Li, Winfred C. Wang, Brenda Martin, Phillip Seaman, MaryLou MacDermott, Tally Hustace, Lynn W. Wynn, Jennifer McDuffie, Ellen Debenham
Publikováno v:
Blood. 112:1429-1429
Background: Factors influencing participation in clinical trials have been reported, but few studies analyze the combination of issues which affect overall patient accrual. When designing clinical trials, investigators are aware that some potential s